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Previewskinases such as CDK4, monoclonal anti-
bodies targeting receptors like IGF-R1 or
EGFR, and peptide-mimetic MDM2
protein-interaction inhibitors that can
rescue wt-p53 functions (Figure 1). We
can now include the clinically relevant
p53 protein interaction from Twist1 as
a key target to evaluate for its therapeutic
potential. There is enormous promise in
drugging such protein-protein interac-
tions, as this forms an untapped and
large landscape for drug development
(Crunkhorn, 2011).
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The first two murine models of IDH1(R132H) mutation provide mechanistic insights into transformation. In
hematopoietic cells, inhibition of TET2 and histone demethylases leads to epigenetic alterations and accu-
mulation of hematopoietic precursors. In the central nervous system, inhibition of collagen and prolyl hydrox-
ylases lead to altered microenvironment and defective angiogenesis.Large-scale sequencing efforts have iden-
tified novel genes that are somatically
mutated in cancer. Two of the more unex-
pected genes that have been implicated
as recurrent mutational targets are IDH1
and IDH2, which encode isocitrate dehy-
drogenase-1 and isocitrate dehydroge-
nase-2, respectively. These enzymes
catalyze the conversion of isocitrate to
a-ketoglutarate (aKG) in anNADP+depen-
dent manner. Mutations in IDH1 were first
identified in colorectal cancer, and later,
mutations in IDH1/IDH2 were identified in
brain tumors, with >70% incidence in
secondary gliomas (Yan et al., 2009).
Through whole-genome sequencing of
a case of acute myeloid leukemia (AML),
an IDH1 mutation was identified, and
IDH1/IDH2 mutations were subsequently
found in 12%–18% of AML cases (Mardis
et al., 2009). Mutations have also beenidentified in thyroid cancers, chondrosar-
comas, and cholangiocarcinomas.
At first it was puzzling how basic meta-
bolic enzymes could be linked to cancer.
The mutant IDH1/IDH2 enzymes have
decreased enzymatic activity known at
that time. However, the observations
that the mutations always presented as
heterozygous and at highly conserved
arginine residues are more consistent
with these being gain-of-function. This
led to the critical finding that these
mutants acquired neomorphic activity
converting aKG to 2-hydroxyglutarate
(2HG) (Dang et al., 2009; Ward et al.,
2010). Tumor samples harboring these
mutations had 2HG at levels up to 100-
fold greater than controls. Besides being
an intermediate in the Krebs cycle, aKG
is involved in other biochemical pro-
cesses, including synthesis of glutamate,transamination of amino acids, generation
of NADPH, and acting as a cofactor for
dioxygenase enzymes. The structural
similarity between 2HG and aKG sug-
gested that other enzymatic processes
maybecompetitively inhibitedbyelevated
2HG levels (Xu et al., 2011) (Figure 1).
Through analysis of global DNAmethyl-
ation profiles in glioblastomas (GBMs),
a distinct profile termed CpG island meth-
ylator phenotype with elevated genomic
methylation was found to be closely asso-
ciated with IDH1 mutations (Noushmehr
et al., 2010). Subsequently, it was discov-
ered that IDH1/IDH2 mutations were
mutually exclusive with TET2 mutations,
a gene encoding an aKG-dependent
enzyme involved in DNA demethylation,
suggesting that these proteins are in-
volved in the same pathway. Biologic
significance was demonstrated throughptember 11, 2012 ª2012 Elsevier Inc. 285
Figure 1. IDH1 Mutant Disrupts Multiple Cellular Processes
IDH1(R132H) produces 2HG, which inhibits aKG dependent dioxygenases.
Inhibition of TET enzymes blocks 5-hydroxy methylcytosine modification,
which leads to cytosine demethylation. Inhibition of JmjC-HDs leads to altered
histone methylation on multiple histone H3 lysine residues. Inhibition of
C-P4H1-3 and PLOD1-3 prevents proper prolyl and lysyl hydroxylation of
collagen, which are required for their proper maturation. Inhibition of PHDs
prevents HIF1a prolyl hydroxylation and subsequent ubiquitination by the
von Hippel Lindau protein and degradation by the proteasome. A combination
of these effects leads to epigenetic changes in the bone marrow, resulting in
altered differentiation of hematopoietic progenitors and dysfunctional angio-
gensis in the brain, resulting in CNS hemorrhage. IDH1/IDH2 isocitrate dehy-
drogenase-1 and isocitrate dehydrogenase-2, IDH1*/IDH2* mutant IDH1 or
IDH2; aKG, a-ketoglutarate; 2HG, 2-hydroxygluatare; TET, Tet methylcytosine
dioxygenase; JmjC-HD, Jumonji-C domain-containing histone demethylases;
C-P4H1-3, collagen prolyl 4-hydroxylase 1-3; PLOD1-3, procollagen-lysine,
2-oxoglutarate 5-dioxygenases 1-3; PHD, prolyl hydroxylase domain-contain-
ing proteins; HIF1a, hypoxia-inducible factor 1a; C, cytosine; P, proline;
K, lysine; Ub, ubiquitin; me, methyl; OH, hydroxy.
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assays in which expression
of IDH1/IDH2 mutant pro-
teins or functional loss of
TET2 resulted in similar
changes that promote leuke-
mogenesis (Figueroa et al.,
2010). More recent work has
also identified histone deme-
thylases as potential aKG-
dependent targets (Lu et al.,
2012).
Two recent papers pub-
lished by Sasaki et al. re-
port the phenotype of mice
expressing the IDH1(R132H)
mutant from the endoge-
nous Idh1 locus. The first
paper reports the pheno-
type of mice expressing
IDH1(R132H) targeted to the
hematopoietic system (Sa-
saki et al., 2012a). These
mice develop hematologic
abnormalities, including ane-
mia, splenomegaly, and ex-
tramedullary hematopoiesis.
Thesemice are characterized
by hematopoietic stem/pro-
genitor expansion, including
increased numbers of LSK
(LinSca1+cKit+) cells and
lineage restricted progenitors
(CD150CD48+). Using en-
hanced representation bisulfite sequenc-
ing, the authors found that LSK cells
from these mutant mice had significantly
more methylated CpG sites compared
to control LSK cells, most notably at
promoter and intragenic regions. This
increased global methylation is hypothe-
sized to be secondary to inhibition of
TET2. Likewise, they find increased
histone methylation, particularly for
H3K4me3 and H3K79me2, chromatin
marks that are associated with active
or poised transcription. Inhibition of
Jumonji-C domain-containing histone de-
methylases by 2HG likely underlies this
observation. These findings agree with
results in IDH1/IDH2 mutant AMLs that
have a hypermethylation profile with
a significant overlap in commonly hyper-
methylated genes. They also extend our
mechanistic understanding of leukemo-
geneisis. In the subset of AMLs caused
by translocations of the mixed lineage
leukemia (MLL) gene, it is believed
increased H3K79me2 activity through286 Cancer Cell 22, September 11, 2012 ª20recruitment of DOT1L contributes to dys-
regulated gene expression, and it is
possible that inhibition of DOT1L might
reverse the phenotypic effects of mutant
IDH alleles on hematopoietic function.
In the second paper, Sasaki et al.
(2012b) describe the phenotype of mice
expressing IDH1(R132H) in the CNS using
two cre strains (Nestin and GFAP). These
mice develop perinatal lethality due to
intracerebral hemorrhage. They noted
variable penetrance in the GFAP-cre
line; phenotypic severity correlated with
levels of 2HG expression. This abnormal
vascular development appears to be
a consequence of 2HG-mediated inhibi-
tion of the dioxygenases that regulate
collagen maturation and hypoxia-induc-
ible transcription factors (HIF)1a and
HIF2a degradation. Type IV collagen is
a component of the basement membrane
between astrocytes and endothelial
cells. Its maturation depends on hydroxyl-
ation by procollagen-lysine, 2-oxogluta-
rate 5-dioxgenases 1-3 (PLOD1-3) and12 Elsevier Inc.collagen prolyl-4-hydroxy-
lases 1-3 (C-P4H1-3). In Idh1
mutant mice, immature forms
of collagen accumulate, and
collagen fails to properly
deposit along blood vessels.
Accumulation of immature
collagen also leads to a sec-
ondary endoplasmic retic-
ulum (ER) stress response,
which may be responsible
for the increased apoptosis
seen in the brain of mice ex-
pressing mutant Idh1. In addi-
tion, HIF1a/HIF2a are regu-
lated by prolyl-hydroxylation,
which leads to degradation
by the ubiquitin-proteasome
pathway through von Hippel
Lindau (VHL) protein-medi-
ated E3 ligase activity. The
prolyl hydroxylase domain-
containing proteins (PHDs)
that regulate HIF1a/HIF2a
stability belong to the dioxy-
genase family and are likewise
another potential target of
2HG inhibition. In mutant
mice, HIF1a accumulates,
and the expression of HIF1a
target genes, including Vegf,
concomitantly increases. The
combination of defective
vessel integrity, increased ERstress, and elevated angiogenic signaling,
likely leads to the intracerebral hemor-
rhage seen with brain-specific expression
of IDH1(R132H).
Unlike the hematopoietic model, the
CNS model of IDH1(R132H) expression
does not suggest a putative mechanism
for how glial cells expressing mutant IDH
are transformed. Although abnormal
angiogensis is a hallmark of GBM and
brain tumor progression, IDH1 mutations
are an early event, with mutations de-
tected more frequently in low-grade
gliomas and secondary GBMs than in
primary GBMs (Yan et al., 2009). Contrary
to their expectation, the authors noted
lower levels reactive oxygen species in
mutant brain cells compared to controls.
In contrast to the hematopoietic model,
the authors did not note significant
changes in histone methylation in the
brain. Furthermore, although there was
a decrease in 5-hydroxymethylcytosine
(the product of TET2 enzymatic activity),
the authors did not provide evidence of
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flected in the lack of changes in the differ-
entiation pattern of CNS stem cells and
failure of these mice to show evidence of
glioma formation even with age.
These mouse models serve as an
important step in modeling oncogenic
IDH alleles and will undoubtedly serve as
the basis for studies combining onco-
genic IDH alleles with other mutations
known to co-occur with IDH1/IDH2muta-
tions in AML, glioma, and other malignan-
cies. These results also raise fundamental
biochemical questions as to whether spe-
cific enzymes are differentially inhibited
by 2HG in a tissue-specific manner, and
which of the many enzymes inhibited by
2HG are essential for transformation. In
addition, further work is needed to bring
greater resolution as to how epigenetic
repatterning at key genes contributes
to oncogenic transformation. Taken
together, these studies demonstrate that
IDH1/IDH2mutations will have pleiotropic
effects in different contexts that contri-bute to transformation in different tumor
types. Moreover, the development of
these models provides an avenue for
preclinical testing of IDH1/IDH2 inhibitors,
such that we learn whether this repre-
sents a potential therapy for the subset
of patients with neomorphic IDH disease
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Cancer vaccines are beginning to show signs of clinical activity, but major uncertainties remain regarding
antigen selection, strategy for immune stimulation, patient stratification, andmonitoring of elicited response.
A new study of peptide vaccines in advanced renal cell carcinoma patients provides important insights into
these central issues.Recent clinical successes have validated
the long-standing idea that therapeutic
manipulation of endogenous immunity
may achieve meaningful anti-tumor ef-
fects (Mellman et al., 2011). Perhaps the
most compelling evidence marshaled to
date derive from studies of blocking
monoclonal antibodies against key nega-
tive immune regulatory molecules,
such as cytotoxic T lymphocyte-associ-
ated antigen-4 and programmed death-1,
which achieve durable tumor regressions
and/or disease control in several typesof malignancies. These therapeutic ap-
proaches are limited in selectivity for
amplifying anti-tumor immune responses,
however, and thereby sometimesprovoke
serious inflammatory reactions in normal
tissues.
Compared to targeting immune regula-
tory pathways, cancer vaccines offer
a stronger potential for focusing immune
reactions toward tumor-specific and
tumor-associated antigens, but the clin-
ical impact of these strategies thus far
has been more modest, highlighting theneed for further optimization (Mellman
et al., 2011). Vaccines aim to load den-
dritic cells (DCs), the professional antigen
presenting cells of the immune system,
with relevant cancer antigens and
stimulate DCs to mature and migrate to
regional lymph nodes, where they may
efficiently prime tumor antigen-specific
T and B lymphocytes. The activated
T cells, particularly cytotoxic CD8+ lym-
phocytes but also CD4+ effectors, may
in turn traffic systemically to metastatic
deposits and thereupon effectuate tumorptember 11, 2012 ª2012 Elsevier Inc. 287
